Table 1 Comparisons between RA patients with and without migraine
From: Migraine in patients with rheumatoid arthritis and its relation to disease activity
Parameter | Non-migraine group | Migraine group | χ2 | P value |
|---|---|---|---|---|
N (%) | 158 (71.8%) | 62 (28.2%) | ||
Qualitative data | ||||
Sex | 0.298 | 0.585 | ||
Male | 25 (15.8%) | 8 (12.9%) | ||
Female | 133 (84.2%) | 54 (87.1%) | ||
Current smoking | 18 (11.4%) | 9 (14.5%) | 0.404 | 0.525 |
Positive RF | 109 (69%) | 43 (69.4%) | 0.003 | 0.958 |
Positive anti-CCP | 124 (78.5%) | 54 (87.1%) | 2.140 | 0.144 |
Rheumatoid disease activity | FET | < 0.001 | ||
Remission (DAS28 < 2.6) | 62 (39.2%) | 6 (9.7%) | ||
Low (DAS28 ≥ 2.6 to ≤ 3.2) | 64 (40.5%) | 17 (27.4%) | ||
Moderate (DAS28 > 3.2 to ≤ 5.1) | 31 (19.6%) | 37 (59.7%) | ||
High (DAS28 > 5.1) | 1 (0.6%) | 2 (3.2%) | ||
Functional losses (MHAQ) | 21.243 | < 0.001 | ||
Mild (MHAQ < 1.3) | 99 (62.7%) | 21 (33.9%) | ||
Moderate (MHAQ 1.3 to 1.8) | 46 (29.1%) | 23 (37.1%) | ||
Severe (MHAQ > 1.8) | 13 (8.2%) | 18 (29%) | ||
Fibromyalgia | 1 (0.6%) | 14 (22.6%) | FET | < 0.001 |
Sjogren's syndrome | 0 (0%) | 7 (11.4%) | FET | < 0.001 |
NSAIDs use | 13 (8.2%) | 5 (8.1%) | 0.002 | 0.968 |
Corticosteroid use | 22 (13.9%) | 9 (14.5%) | 0.013 | 0.910 |
Methotrexate use | 114 (72.2%) | 38 (61.3%) | 2.460 | 0.117 |
Sulfasalazine use | 12 (7.6%) | 5 (8.1%) | FET | 1.000 |
Leflunomide use | 7 (4.4%) | 3 (4.8%) | FET | 1.000 |
Anti-TNF-α use | 4 (2.5%) | 3 (4.8%) | FET | 0.405 |
Hydroxychloroquine use | 77 (50%) | 29 (46.8%) | 0.185 | 0.667 |
Z value | P value | |||
|---|---|---|---|---|
Quantitative data | ||||
Age (years) | 42 (35–47) | 41 (35.8–49) | −0.037 | 0.971 |
Rheumatoid disease duration (years) | 8 (5–9.25) | 8 (5–10) | −0.227 | 0.820 |
ESR | 55 (49–60) | 64.5 (50.8–79) | −3.766 | < 0.001 |
CRP | 37 (33–40) | 44 (35–55) | −4.660 | < 0.001 |
Disease Activity Score (DAS-28) | 2.8 (2.5–3.2) | 3.9 (2.9–4.1) | −6.727 | < 0.001 |
MHAQ | 1.0 (1.0–1.40) | 1.4 (1.0–2.0) | −4.436 | < 0.001 |